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Characteristics of Patients With Universal Vitiligo and Health-Related Quality of Life

L
ittle is known about universal vitiligo, a rare type of vitiligo in which more than 80% of the skin is depigmented. We do not know whether patient characteristics differ from those in the more common types of vitiligo. Moreover, nothing is known about healthrelated quality of life (HRQOL) in these patients. The aims of this study were to describe characteristics and HRQOL of patients with universal vitiligo and to compare these with the characteristics and HRQOL of patients with general vitiligo.
Methods. All adult patients (Ͼ18 years) having universal vitiligo diagnosed at the Netherlands Institute for Pig- ment Disorders (NIPD), Amsterdam, were mailed a package containing information about the study, an informed consent form, a questionnaire booklet with a questionnaire on patient characteristics and 2 QOL questionnaires-the 36-item Dutch Short Form (SF-36) 1 and the 29-item Dutch Skindex (Skindex-29) 2 -and a stamped return envelope. In case a patient did not respond, the patient was reminded by telephone with a maximum of 3 follow-up calls.
A cohort of 245 adult patients with general vitiligo, referred to the NIPD in 2006, served as a comparison group. Each patient with universal vitiligo was matched for sex and age with 2 patients of the comparison group.
To detect a priori differences between respondents and nonrespondents, age and sex were compared using a 2 test and a t test, respectively. The characteristics of patients with universal vitiligo were compared with those of patients with general vitiligo, using a t test or a 2 test. The means of the scale scores and the summary scores of the SF-36 and the Skindex-29 of patients with universal vitiligo were compared with those of patients with general vitiligo, using t tests. Effect sizes were calculated. 3 An effect size of 0.3 can be considered as clinically important. 4 The level of significance was set at PϽ.05.
Results.
A total of 65 patients were eligible for this study. Six patients did not want to participate in the study, and 4 patients did not respond. The 55 patients included in this study (response rate, 85%) ranged in age from 22 to 77 years (median age, 52 years). The respondents and nonrespondents did not differ significantly with respect to age and sex. Patient characteristics and P values are presented in Table 1 .
Patients with universal vitiligo reported significantly more comorbidities than the patients with general vitiligo (P Ͻ .05). The most frequently mentioned comorbidities were thyroid dysfunction, rheumatoid arthritis, diabetes mellitus, and alopecia areata. Patients with universal vitiligo seemed to experience rheumatoid arthritis more often (15%) than patients with general vitiligo (3%; PϽ .05). Furthermore, alopecia areata was reported in 4 patients with universal vitiligo, whereas none of the patients with general vitiligo reported this comorbidity (P Ͻ .05). Patients with universal vitiligo reported having more family members (47%) with vitiligo than patients with general vitiligo (35%; P Ͻ .05). Of the family members of patients with universal vitiligo, 24% also had universal vitiligo. Table 2 shows the results of HRQOL outcomes. Statistically significant differences were seen in the Physical Functioning, Bodily Pain, and General Health domains and in the Physical Component Summary of the SF-36, with a poorer physical HRQOL in patients with universal vitiligo. Scores on the Functioning scale of the Skindex-29 were significantly higher in patients with universal vitiligo, indicating more functional impairment in these patients compared with patients with general vitiligo (P Ͻ .05). The effect sizes of these statistically significant results can be considered clinically important. 
